Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Fusion proteins play an essential role in the biosciences but suffer from several key
limitations, including the requirement for N-to-C terminal ligation, incompatibility of …

The ability of monoclonal antibodies to specifically bind a target antigen and neutralize or
stimulate its activity is the basis for the rapid growth and development of the therapeutic …

Protein bioconjugation is an increasingly important field of research, with wide-ranging
applications in areas such as therapeutics and biomaterials. Traditional cysteine and lysine …

Over the past few decades, the complexity of molecular entities being advanced for
therapeutic purposes has continued to evolve. A main propellent fueling innovation is the …

We describe a new technique in protein synthesis that extends the existing repertoire of
methods for protein modification: A chemoselective reaction that induces reactivity for a …

Introduction In the field of bioconjugates, the focus on antibody–drug conjugates (ADCs)
with novel payloads beyond the traditional categories of potent cytotoxic agents is …

Bispecific antibodies (bsAbs) target two different epitopes. These are an up-and-coming
class of biologics, with two such therapeutics (emicizumab and blinatumomab) FDA …

Conjugates of therapeutic oligonucleotides (ONs) including peptide conjugates, provide a
potential solution to the major challenge of specific tissue delivery faced by this class of …

Protein therapeutics have gained momentum in recent years and become a pillar in treating
many diseases and the only choice in several ailments. Protein therapeutics are highly …